First Half of 2025: Solid Growth, Investments and Pipeline Progress Pave the Way for Two Key ...

Boehringer eyes H2 drug launches after strong H1 growth

Boehringer Ingelheim is preparing for multiple drug launches in the second half of 2025, following strong first-half financial results that saw the company report a 6.3%* rise in group net sales to €14.0 billion ($16 billion).

First half of 2025: Solid growth, investments and pipeline progress pave the way for two key ...

Group net sales grow by 6.3%* to EUR 14.0 billion, driven by Human Pharma (EUR 11.3 billion) and Animal Health (EUR 2.6 billion)Regulatory submissions underway for zongertinib and nerandomilast, with launches expected in H2 2025Strategic investments in R&D and global…

First half of 2025: Solid growth, investments and pipeline progress pave the way for two key launches in H2

Group net sales grow by 6.3%* to EUR 14.0 billion, driven by Human Pharma (EUR 11.3 billion) and Animal Health (EUR 2.6 billion)Regulatory submissions underway for zongertinib and nerandomilast, with launches expected in H2 2025Strategic investments in R&D and global…